Once-Weekly Semaglutide in Adolescents with Obesity

NEJM

November 2, 2022

Enlaces

https://www.nejm.org/doi/full/10.1056/NEJMoa2208601#.Y2NUsp6AoXI.twitter

Artículos Relacionadas

Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Transgender healthcare: metabolic outcomes and cardiovascular risk

The metabolic and circadian signatures of gestational diabetes in the postpartum period characterised using multiple wearable devices

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline

Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study

Evolution of the Primary Aldosteronism Syndrome: Updating the Approach

Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism

Management and follow-up strategies for patients with head and neck paraganglioma

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

✍🏻⚠️ Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

Agenda

Enero 2025

Lun	Mar	Mié	Jue	Vie	Sáb	Dom
30	31	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31	1	2

Top